TWA
PSTX

TCI Wealth Advisors’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

TCI Wealth Advisors’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-266
Closed -$820 – 2363
2023
Q1 		$820 Buy
+266
New +$1.59K ﹤0.01% 2139

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

TCI Wealth Advisors's PSTX Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q2 2023, closing a stake of 266 shares — an estimated $820 sold.

TCI Wealth Advisors first reported a position in PSTX in Q1 2023 and held it in 1 quarter. The position peaked at $820 in Q1 2023. 94 funds tracked by Wall St. Rank hold PSTX as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 266 Poseida Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $820.
  • TCI Wealth Advisors first reported a position in Poseida Therapeutics, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • TCI Wealth Advisors's Poseida Therapeutics, Inc. Common Stock position peaked at $820 in Q1 2023.
  • 94 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.